Loading stock data…
Acurx Pharmaceuticals (ACXP)
$1.67+0.15 (+9.87%)
Market OpenUpdated 3:07 PM EDT
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Acurx Pharmaceuticals, Inc. in the Healthcare sector is trading at $1.66 with a market capitalization of $7M. Wall Street consensus targets $17.00 (3 analysts), implying a +927.2% move over the next 12 months. The stock is currently near its 52-week low of $1.33, remaining 50.3% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +927.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$1.72M↓ | -$1.62M↑ | -$2.03M↑ | -$2.27M↓ | -$2.18M |
| Net Income | -$1.68M↓ | -$1.58M↑ | -$1.99M↑ | -$2.25M↓ | -$2.15M |
Peer Comparison
JNJUNHPFE
Fundamentals
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the po...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.70M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-106.92%
Volume
Today's trading volume
150,158
Recent News
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's Why
Acurx Pharmaceuticals (ACXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Acurx Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
Moby summary of Acurx Pharmaceuticals, Inc.'s Q1 2026 earnings call
Is Acurx Pharmaceuticals (ACXP) Stock Outpacing Its Medical Peers This Year?
Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Apyx Medical (APYX) have performed compared to their sector so far this year.
Acurx Pharmaceuticals Inc (ACXP) Q4 2025 Earnings Call Highlights: Financial Growth and ...
Acurx Pharmaceuticals Inc (ACXP) reports improved financial stability and significant progress in clinical trials, despite ongoing challenges.
Can Acurx Pharmaceuticals (ACXP) Climb 226.3% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Acurx Pharmaceuticals (ACXP) points to a 226.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.